

Clinical Decision Support for Parents through Mobile Applications: A Systematic Assessment of Pediatric Fever Management Apps

Chloe Joosen^a, Jaan Toelen^{b,c,d}, Willeke Asscherickx^e

^a Faculty of Medicine, KU Leuven, Belgium

^b Leuven Child and Youth Institute, KU Leuven, Belgium

^c Department of Paediatrics, University Hospitals Leuven, Belgium

^d Department of Development and Regeneration, KU Leuven, Belgium

^e Department of Paediatrics, AZ Diest, Belgium

w.asscherickx@azdiest.be

Keywords

Medical decision tools ; mobile applications ; triage ; fever.

Abstract

Objective

This study aimed to identify existing apps for paediatric fever management and compare their decision algorithms with current evidence-based guidelines.

Methods

From May to July 2022, mobile applications were systematically searched in the Apple App Store and Google Play Store using specific terms. The apps underwent four rounds of screening to match predefined criteria. Each app was evaluated by five independent reviewers using the Mobile Application Rating Scale (MARS). The decision support algorithms of each app were analysed for adherence to existing fever management recommendations, including the NICE guidelines for children under five years of age and the Schmitt-Thompson triage protocol for children under and over three months of age.

Results

Out of 878 apps retrieved, 6 met the selection criteria and were 3 finally assessed. The apps scored high on overall quality, averaging a MARS rating of 4.3 out of 5. Kinsa and FeverApp scored the highest (4.4 out of 5), followed by FeverFriend (4.0 out of 5). FeverFriend showed the highest adherence to the NICE guidelines, followed by Kinsa and FeverApp. For the Schmitt-Thompson protocol, Kinsa showed the highest adherence, followed by FeverFriend and FeverApp.

Conclusion

The availability of evidence-based fever management apps with parental decision support systems is limited. Kinsa emerged as the top-performing app based on quality assessment.

Introduction

Fever, defined as a body temperature exceeding the normal range (36.6°C to 37.9°C), is a natural physiological response that boosts the immune system and combats infection, potentially shortening the duration of illness (1). It is a common childhood condition as children between the ages of 3 and 36 months typically experience about six febrile episodes annually (2). This underscores the fact that fever is usually a symptom of other illnesses rather than a disease itself (3). Although fever in children under five is often linked to benign viral infections, it can also be associated with serious health issues.

This makes fever management very challenging for parents, mostly due to misconceptions about its significance and effects (4). Caregivers fear harm either from the fever itself or the underlying illness (5). They are thus confronted with the decision to treat symptoms at home or seek medical attention, which leads to overuse primary care and specialized secondary care systems (6,7).

The surge in mobile technology usage has led to the emergence of health-related applications, including those aimed at assisting parental decision-making. These apps, which include symptom checkers and self-triage tools, promise to be transformative, yet their integration of evidence-based medicine remains inadequately examined (8, 9, 10). This study focuses on evaluating mobile applications equipped with parental decision support systems (PDSS) for the management of paediatric fever. We aim to compare these apps' decision-making algorithms with current evidence-based guidelines and examine their

potential in aiding caregivers to make informed choices about managing fever, which could help reduce unnecessary use of antipyretics and reduce the burden on healthcare facilities.

Material and Methods

Search Strategy

The initial identification of existing triage applications, was obtained by entering the keywords "pediatrics" OR "fever" OR "pediatrics, fever" OR "pediatrics, symptom" OR "fever, children" OR "fever, child" OR "fever, symptom" OR "febrile, symptom" in the search engines of both the Apple App store for iOS and the Google Play store for Android. Searches were performed within these digital distribution platforms from May to July 2022.

After the identification process, preliminary selection and assessment of mobile applications was based upon a prespecified set of inclusion and exclusion criteria as defined in Table 1. Selected applications were subject to four rounds of screening.

Since the apps were obtained by systematic searches in two sources (the Apple App Store and the Google Play Marketplace) using multiple search terms, results were screened for duplicates. Duplicate apps, i.e. identical features in the same app listed independently in both app stores or listed in the same app store using different search terms, were excluded in the first round. Applications by the same developer, similarly named, but not having identical feature sets were treated as two individual apps.

Table 1: Inclusion and exclusion criteria.

Main inclusion criteria	Specific mobile health criteria	Exclusion criteria
<ul style="list-style-type: none"> • Children health assessment • Pediatrics • Fever management support 	<ul style="list-style-type: none"> • Parental decision support system • No exclusive focus on fever monitoring and fever registration • No exclusive focus on telemedicine/ video consultation • Ability to function independently of a medical device • Ability to function without possession of a US phone number 	<ul style="list-style-type: none"> • Games • No relation to healthcare and medical services • No English user interface • Health care workers as primary audience

Additionally, games or applications without presence of English user interface were excluded in the first round as well. The second round of screening was performed based on title/name and available summary description within the app stores. Applications that were non-compatible with main inclusion criteria were excluded. The general target population in this study includes non-clinical app users, i.e. parents and caregivers. Apps aimed at the provision of fever management guidance within clinical settings, that is with target users being physicians and healthcare professionals, were also excluded as a part of round two.

In the third round, the remaining applications were downloaded and manually assessed for evaluation of specific mobile health criteria. The apps inconsistent with our criteria were eliminated. In the fourth round apps with main focus on fever management in children were differentiated from those that provide fever management decision support, without fever management in children being the app's main target, by dividing them into two groups. Thus, the first group of apps focuses entirely on assisting parents who are dealing with a febrile child while the second group of apps provide a decision

support system for numerous symptoms in a variety of ages, including fever. The flowchart in Figure 1 illustrates the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology described.

Quality assessment: the Mobile Application Rating Scale

First, the applications were independently evaluated by a team of five reviewers (parents without medical background) using the Mobile Application Rating Scale (MARS). MARS is a widely used standardized tool developed by the Queensland University of Technology. It provides a multidimensional measure of mobile health app quality by assessment in three sections. The first section is divided into four objective dimensions, i.e. engagement, functionality, aesthetics, and information quality. In short, the scale measures whether an app is interesting, interactive (e.g. sends alerts, messages, reminders or feedback) and easy to learn. It analyses the gestural design and examines the quality and quantity of information provided. In the first section nineteen items are rated on a 5-point scale (1= inadequate, 2= poor, 3= acceptable, 4= good, and 5= excellent). The mean score of each dimension is then calculated and used to compute the app overall quality score (11, 12). The second and third section, being the app subjective quality score and the app specific quality score, are equally determined by rating of respectively 4 and 6 additional items. Supplementary, ambiguous items were discussed and clarified to ensure full comprehension of the scale (13).

Figure 1: Flowchart of the selection process.




Table 3: Adherence of existing fever management apps to the Smitt- Thompson protocol concerning fever in children < and > 3 months of age.

Smitt- Thompson protocol	Kinsa	FeverFriend	FeverApp*	Points of comparison
FEVER				
No fever (T ≤ 38°C) Under 3 months Fever (T ≤ 39°C) Between 3-6 months Fever (T ≤ 40.6°C) Above 6 months Rectal - type of thermometer unspecified Oral - type of thermometer unspecified (not under 3 months) Infra- red temporal artery thermometer Infra- red tympanic thermometer (not under 6 months) Fever < 3 days No shaking chills High Fever (T ≥ 39°C) 3-6 months	No Fever (T < 38°C) Under 3 months No Fever (T < 38°C) Between 3-6 months No Fever (T < 40°C) Above 6 months Rectal- type of thermometer unspecified * Infra- red tympanic thermometer * - age unspecified	No Fever (T ≤ 38°C) Under 3 months No Fever (T ≤ 38°C) Between 3-6 months No Fever (T ≤ 40°C) Above 6 months Rectal - digital or chemical thermometer * Oral - digital or chemical thermometer - age unspecified * Infra- red tympanic thermometer - age unspecified	No Fever (T ≤ 38°C) Under 4 months Fever (T > 38°C) Above 4 months Rectal - type of thermometer unspecified * Infra- red tympanic thermometer - age unspecified Fever < 3 days Fever (T > 38°C) Between 3-6 months Fever (T > 38°C) Under 4 months	Fever under 3 months: Both the Feverfriend and Kinsa app identified the symptom as high risk, thereby matching the guideline. The FeverApp app underestimated the symptom compared to the guideline, by classifying it as an intermediate risk of serious illness. The FeverApp app additionally mentioned both 3 months and 4 months as a cut off in age. High Fever between 3 to 6 months: None of the apps matched the guideline perfectly. Both the Feverfriend and Kinsa app identified fever (T ≥ 38°C) between 3 and 6 months as an intermediate risk of serious illness, thereby overestimating the symptom compared to the guideline. The FeverFriend app additionally identified a high fever (T ≥ 39°C) within this age group as a high risk symptom. The FeverApp app did not mention this symptom. Very high fever: The guideline identified a cut off of 40.6 °C body temperature. Both the FeverFriend and Kinsa app specified a different cut off, thereby not matching the guideline. The FeverApp app did not mention this symptom. Fever duration: The FeverFriend and the FeverApp app both identified a 'fever duration > 3 days' as an intermediate risk symptom, thereby matching the guideline. However, the FeverFriend app mentioned another cut off in time of 5 days, classifying a 'fever duration > 5 days' as a high risk symptom and thereby not matching the guideline in its entirety. The Kinsa app did not mention this symptom. Type of measurement: Every app recommended fever measurement rectally, thereby matching the guideline. However, the guideline specifies the age from which oral or tympanic fever measurements are recommended. Due to absent age specification by the apps, no additional match to the guideline could be concluded. Rigors: The Kinsa app did not specify a time lapse within the presence of chills and identified the 'presence of chills' as a low risk symptom, thereby underestimating the symptom compared to the guideline. The FeverFriend and FeverApp app did not mention the symptom.
Fever > 3 days Fever (T ≥ 38°C) Under 3 months Very high Fever (T ≥ 40.6°C)	Fever (T ≥ 38°C) Under 3 months High Fever (T ≥ 40°C)	Fever 3-5 days Fever (T ≥ 38°C) Under 3 months High Fever (T > 39°C) Between 3-6 months Very high Fever (T > 41°C) Fever > 5 days	Fever > 3 days	
Shaking chills > 30 minutes	Chills Fever (T ≥ 38°C) Between 3-6 months High fever (T > 40°C) Above 6 months			
SKIN CONDITION AND COLOR				
Normal color of skin, lips and tongue No rash	Normal color of skin and lips No rash Rash Above 2 years	Normal color of skin No rash	No rash Blanching rash Present for < 3 days	
	Rash Under 2 years Hives	Pallor Blanching rash	Blanching rash Present for > 3 days	Color of skin: Both the FeverFriend and Kinsa app identified a bluish skin as a high risk symptom, thereby matching the guideline. The FeverApp app did not include skin color in its triage system. Rash: The Kinsa app identified the presence of 'purple or blood-colored spots' as a high risk symptom, thereby matching the guideline. The FeverFriend app and the FeverApp app did not specify a 'non-blanching rash'. Due to absent content specification by the apps, no match to the guideline could be concluded.
Bluish lips or face Widespread rash with purple or blood-colored spots or dots	Bluish skin or lips New purple or blood-colored spots/dots Blisters, sores or pus Rash developing after taking new medication Sudden and severe skin peeling	Grey, bluish, purplish skin Non-blanching rash	Non-blanching rash	
RESPIRATORY				
No signs of dyspnea No spitting of saliva	No signs of dyspnea No spitting of saliva or fluids	No signs of dyspnea Difficult or laboured breathing ≤ 3/5 * Slight wheezing	No signs of dyspnea Enforced or constrained breathing	Signs of dyspnea: The Kinsa and FeverApp app both defined shortness of breath by using a series of clinical observations. The Kinsa app matched some clinical observations compared to the guideline by classifying 'grunting' and being 'unable to finish a sentence' as a high risk symptom. Both the FeverFriend and the Kinsa app identified difficult breathing as a high risk symptom, thereby matching the guideline. However, the FeverFriend app defined shortness of breath through a scale, thereby making comparison to the guideline difficult. The '> 4/5' was concluded as similar to 'struggling for each breath', therefore a partial match to the guideline was concluded. The scale is specified below. The FeverApp app matched no clinical observations to the guideline. Excessive spitting, drooling: The Kinsa app identified the symptom as a high risk symptom, thereby matching the guideline. The FeverFriend and FeverApp app did not mention this symptom.
Difficult breathing, struggling for each breath Unable to speak or cry Grunting	Difficult breathing Unable to finish a sentence Grunting Retractions	Difficult or laboured breathing > 4/5 * Strong wheezing, stridor		
Unable to swallow fluid or excessive spitting	Unable to swallow fluid or excessive spitting			
CIRCULATION AND HYDRATION				
No signs of dehydration	No signs of dehydration	No signs of dehydration Drinking less than normal Last time eating > 12 hours Dry tongue, decreased tears when crying	No signs of dehydration Last time drinking > 8 hours in infants * Dry mucous membrane *	Poor feeding in infants: The FeverFriend app differentiated poor and severely poor feeding by cut off in time. However, since no specification for infants was made by the app, as stated within the guideline, the symptom did not match the guideline perfectly. The FeverApp app classified the symptom 'last time drinking > 8 hours in infants' as an intermediate risk symptom, thereby underestimating the symptom compared to the guideline. The Kinsa app equally did not specify an age group and identified 'last time drinking > 8 hours', thereby not matching the guideline perfectly. Dry mucous membrane: The Kinsa app identified the symptom as a high risk symptom, thereby matching the guideline. The FeverFriend app differentiated a 'dry tongue with decreased tears' from 'absence of tears' by classifying it as an intermediate and high risk symptom, respectively. Since the guideline mentions 'absence of tears' as part of 'dry mucous membrane', classifying 'no tears when crying' as a high risk symptom matched the guideline. However since a dry tongue was identified as an intermediate risk symptom and the guideline mentions 'dry mouth' as part of 'dry mucous membrane', the FeverFriend app only matched the guideline partially. The FeverApp app identified the symptom as an intermediate risk symptom, thereby not matching the guideline.
Poor feeding in infants	Last time drinking > 8 hours	Last time drinking > 12 hours Last time eating > 24 hours	Reduced urine output (Last urination > 6-12 hours) Reduced urine output (Not specified)	Reduced urine output: The FeverFriend app differentiated a reduced urine output from a severely reduced urine output by classifying it as an intermediate risk symptom and a high risk symptom, respectively. The guideline does not specify the symptom in time, therefore 'last urination > 12 hours' was considered a match to the guideline. The Kinsa app identified the symptom as a high risk symptom, thereby matching the guideline. The FeverApp app identified the symptom as an intermediate risk symptom, thereby underestimating it compared to the guideline.
Dry mucous membrane *	Dry mucous membrane *	No tears when crying *		
Reduced urine output	Reduced urine output (Last urination > 8 hours)	Severely reduced urine output (Last urination > 12 hours)		
GENERAL CONDITION AND ACTIVITY				
No altered mental status or decreased activity No signs or irritability or pain Normal usage of all extremities No seizure No bulging fontanelle No stiff neck No painful urination	Normal awareness No signs of irritability or pain No seizure No bulging fontanelle No stiff neck No painful urination	Normal awareness No signs of irritability or pain; not crying or strong crying No swelling or pain of a body part No seizure No bulging fontanelle No stiff neck No painful urination Odd reactions > 5 hours Sleepy Bulging fontanelle Painful urination	No lethargy No signs of irritability or pain No swelling or pain of the joints No seizure No stiff neck Lethargy Swelling of a joint Pain in the limb ≥ 3 days Stiff neck Acting differently, apathy Clouded consciousness Shrill screaming Touch sensitivity First seizure	Altered mental status: An altered mental status was described by the guideline as a confused state with impaired alertness. Both the FeverFriend and the Kinsa app mentioned clinical observations indicating an altered mental status. These symptoms were classified as high risk symptoms, thereby matching the guideline. The FeverApp app defined 'acting differently' and 'apathy' as high risk symptoms. However, since the lack of specificity, comparison to the guideline remained difficult and no match could be concluded. The FeverFriend app defined 'odd reaction > 5 hours' as an intermediate risk symptom. No intermediate risk symptoms were specified by the guideline. Awareness: A limited consciousness or absent awareness was classified as a high risk symptom by all apps, thereby matching the guideline. All apps additionally identified an increased tendency to fall asleep as an intermediate risk symptom. No intermediate risk symptoms were specified by the guideline. Irritability: All the apps identified an inconsolable, weak or high pitched cry or screaming (as a sign of irritability) as a high risk symptom, thereby matching the guideline. The Kinsa and the FeverApp app both additionally identified 'touch sensitivity' as a high risk symptom, thereby matching the guideline in its entirety. Usage of extremities: Avoidance of using an extremity was not mentioned by any of the apps. However, the FeverFriend app did identify 'protection of body part' as a high risk symptom. Since the guideline specified an extremity, 'protection of body part' was considered too broad to match the guideline perfectly. Seizure: The FeverFriend and Kinsa app both identified a febrile seizure as a high risk symptom, thereby matching the guideline. The FeverApp app specified only the first seizure as a high risk symptom, thereby not matching the guideline perfectly. Bulging fontanelle: The Kinsa app identified the symptom as a high risk symptom, thereby matching the guideline. The FeverFriend app underestimated the symptom compared to the guideline, by classifying it as an intermediate risk symptom. The FeverApp app did not mention this symptom. Stiff neck: The FeverFriend and the Kinsa app both identified the symptom as a high risk symptom, thereby matching the guideline. The FeverApp app underestimated the symptom compared to the guideline, by classifying it as an intermediate risk symptom. Painful urination: The FeverFriend app identified the symptom as an intermediate risk symptom, thereby underestimating it compared to the guideline. The Kinsa and FeverApp app did not mention this symptom.
Altered mental status; awake but not alert, not focused, confused or slow to respond Unresponsive or difficult to waken Limp, weak or not moving Inconsolable crying, irritable Cries every time if touched, moved or held Seizure Bulging fontanelle Stiff neck	Not making eye contact, acts 'out of it' or confused Inability to wake up, unresponsive Limp, not moving Inconsolable crying, shrill screaming Touch sensitivity, crying when touched Seizure Bulging fontanelle Stiff neck	No reaction to social cues No awareness Seizure Stiff neck Swelling of body part(s) Protection of body part(s)		
Won't move arm or leg normally Burning feeling or pain with urination				

Statistical Analysis

The MARS scores were subjected to descriptive analysis. Interrater reliability (IRR) of the MARS subscales and total score was additionally determined by calculating the intraclass correlation coefficient (ICC). This statistic allows assessment of rater agreement and is a number found to have a value between 0 and 1. Zero indicating no reliability among raters and one indicating perfect reliability among raters. ICC estimates and their 95% confident intervals were calculated using SPSS statistical package version 28, based on a mean- rating (k=5), absolute- agreement, 2- way mixed- effects model (14).

Quality assessment: adherence to EBM guidelines

Secondly, adherence to existing fever management recommendations was appraised through comparison against the National Institute of Care and Excellence (NICE) guideline on fever in children under five years of age (15). The Schmitt-Thompson triage protocol for fever in children (under 3 months to 3 months to 6 years of age) was also used for evaluation (16). Our goal was to gain a better understanding of the decision algorithm being used in these mobile applications promoting fever management, as well as to review whether the propositions made are in line with existing prespecified evidence and recommendations. Therefore the mobile applications with a main focus on paediatric fever management were each manually run using 5 profiles with 5 different ages, i.e. 1 month, 3 months, 6 months, 1 year and 5 years. Within each age group, the decision support algorithm was mapped by exploration (given that each app contains a decision support system as stated in the specific mobile health inclusion criteria).

By mapping out these answer options, a set of symptoms was identified validating an alteration in advice. These disease symptoms were stratified into a traffic light system. For example, when the app adjusted its guidance to an advice expressing an urgent need for consultation, the present symptom upon which this adjustment was based was qualified within the colour red indicating a high risk of serious illness. When the app adjusted its guidance to an advice expressing a non-urgent need for consultation the present symptom upon which this adjustment was based, was qualified within the colour yellow indicating an intermediate risk of serious illness. When the app's advice was 'home care', expressing an absent need for consultation, the present symptom was qualified within the colour green indicating a low risk of serious illness. The NICE guideline itself includes a traffic light system chart for febrile illness in children under the age of five for identifying the likelihood of serious illness. The Schmitt-Thompson protocol does not use such a system. Therefore this protocol was also converted into a traffic light system chart by stratification of disease symptoms, allowing comparison of features.

Results

Search Results

Out of the 878 apps retrieved from initial searches in the Apple App Store and the Google Play Store, 6 applications matched our prespecified selection criteria. From these 6 apps, 3 apps were additionally excluded given the lack of paediatric fever focus. The results of these applications will therefore not be discussed within this section. The include apps are the Kinsa app, the FeverFriend app and the Feverapp (17, 18, 19).

Evaluation against the NICE guideline

All three applications were evaluated against the NICE guideline using stratification of disease symptoms into five categories, i.e. fever, skin condition and colour, respiration, circulation and hydration, general condition and activity. Within the NICE traffic light chart, 51 disease symptoms were identified. Each symptom was screened for within

the apps' algorithm. Presence of the symptom and stratification within the accurate level of risk according to the guideline, was identified as a match between app and guideline. Absence of the symptom or stratification within an inaccurate level of risk was identified as a no match between app and guideline.

The FeverFriend app showed the highest adherence to the guideline with a total of 26 matches (51%), closely followed by the Kinsa app with a total of 24 matches (47%) and the FeverApp app with a total of 20 matches (39%), respectively. A detailed summary of the results can be found in Table 2.

Evaluation against the Schmitt-Thompson protocol

All three applications were equally evaluated against the Schmitt-Thompson protocol, using stratification of disease symptoms into the five categories. Within the Schmitt-Thompson traffic light chart, 42 disease symptoms were identified. The Kinsa app showed highest adherence to the protocol with a total of 28 matches (67%), followed by the FeverFriend app with a total of 21 matches (50%) and the FeverApp app with a total of 12 matches (29%), respectively. A detailed summary of the results can be found in Table 3.

MARS App Quality Scores

Looking at the first section and including all three applications, the average MARS overall quality score was 4.3 out of 5 with a standard deviation (SD) of 0.2 and a range of 4.0-4.4. Functionality was found to be the highest scoring domain (mean 4.5 [SD 0.4]; range 4.2-4.9), followed by aesthetics (mean 4.4 [SD 0.5]; range 3.9-4.8), engagement (mean 4.1 [SD 0.4]; range 3.7-4.4) and information (mean 4.0 [SD 0.4]; range 3.5-4.2) respectively. Subjective app quality, as a measure of rater satisfaction, was the lowest scoring MARS section (mean 3.5 [SD 0.8]; range 2.6-4.0). Likelihood for behavioural impact, being the third and final section, had an acceptable average score (mean 3.8 [SD 0.5]; range 3.3-4.1). With regard to the total quality rating within the

individual apps, the Kinsa app and the FeverApp app were equally the highest scoring mobile applications

(4.4 out of 5). Within the app specific subjective quality rating, we find similar scores when looking at the Kinsa app and the FeverFriend app (4.0 and 3.9 out of 5 respectively). The FeverApp however scores markedly lower in this section (2.6 out of 5). Independent ratings on the overall MARS total score and the overall subjective quality score of

Table 4: Summary of the Mobile App Rating Scale scores across the 3 reviewed apps.

MARS Scores and Intraclass correlation coefficient					
MARS domain	Kinsa	FeverApp	FeverFriend	Mean [SD] 95% CI)	ICC (95% CI)
Engagement	4.4	4.2	3.7	4.1 [0.4] (3.2 - 5.0)	0.90 (0.47 - 1.00)
Functionality	4.5	4.9	4.2	4.5 [0.4] (3.7 - 5.4)	0.84 (0.25 - 1.00)
Aesthetics	4.4	4.8	3.9	4.4 [0.5] (3.2 - 5.5)	0.89 (0.46 - 1.00)
Information	4.2	3.5	4.2	4.0 [0.4] (3.0 - 5.0)	0.95 (0.68 - 1.00)
Total MARS Quality	4.4	4.4	4.0	4.3 [0.2] (3.7 - 4.8)	0.82 (0.17 - 1.00)
Subjective Quality	4.0	2.6	3.9	3.5 [0.8] (1.6 - 5.4)	0.95 (0.71 - 1.00)
Likelihood of Behavioral Impact	4.1	3.3	4.1	3.8 [0.5] (2.7 - 5.0)	0.95 (0.74 - 1.00)

Abbreviations:

MARS = Mobile Application Rating Scale; SD = standard deviation; ICC = Intraclass correlation coefficient.

the three applications demonstrated an appropriate level of interrater reliability (ICC = 0.82, 95% CI 0.17-1.00 and ICC = 0.95, 95% CI 0.71-1.00 respectively) (17). A detailed summary of the quality assessment scores and ICC of the included apps is presented in Table 4.

Discussion

To our knowledge, our study is the first to evaluate the performance and accuracy of mobile self-assessment applications assisting parents in the assessment of fever in their children. Our research therefore provides insight into whether a mobile application with parental decision support system has the potential to reduce pressure on primary and secondary care clinics in a safe and patient-friendly way.

To date, several studies have investigated the usefulness of mobile applications in different fields of healthcare. Self-assessment tools, based on computerized clinical algorithms have been described in the literature for primary care for children and adults through the use of symptom checker applications (8). Semigran et al. evaluated the triage accuracy of 15 symptom checker tools. In 57% of cases an 'appropriate level of care' was found (20). However, the performance of the mobile application varied depending on clinical severity. Patient evaluations in emergency care showed a markedly higher percentage of correct triage advice (80%) than those for which self-care was used (33%) (20). Verzantvoort et al. assessed a self-triage app for several symptoms in the context of acute primary care. An accurate level of care was advised in 81% of cases (8). Our study identified remarkably lower percentages. On average the applications advised an appropriate level of care in 46% and 48% of cases, respectively, compared with the NICE guideline and the Schmitt-Thompson protocol. Self-assessment tools as described in the studies mentioned above, have been promoted as a means of reducing unnecessary office visits. However, analysis of these tools in the past has identified a risk-adverse tendency. On one hand over-triaging may improve patient safety since it lowers the chances of missing a red flag symptom. On the other hand overly cautious triaging by the mobile applications might encourage consultation and cause unnecessary care seeking. In our study, no tendency towards risk adverseness could be identified within the FeverFriend App or the FeverApp app. The Kinsa app however, did show an over-triaging propensity.

Fever management advice was compared to two sets of guidelines. The NICE guideline concerning fever management under the age of 5 on one hand and the Schmitt-Thompson protocol concerning fever under and above the age of 3 months on the other. The National Institute for Health and Care Excellence is an executive non- departmental public body in England known to publish updated, EBM recommendations guiding health promotion in a (cost-) effective and safe manner (15). Schmitt-Thompson Clinical Content is the leading source of telephone triage guidelines in North America, providing high quality protocols offering practical evidence-based decision support (16). In our study 3 mobile applications were assessed. The FeverFriend App was developed under direction of the University of Pecs in Hungary. The FeverApp was similarly developed under direction of the University of Witten in Germany, in cooperation with the Professional Association of Paediatricians (BVKJ) and the German Society for Paediatric and Adolescent Medicine (DGKJ). The Kinsa App was created by Kinsa Inc., a health technology company headquartered in the United States of America. Both European and American applications were thus included within this study. Identical selection of a European and American guideline limited the bias in results that arises from comparing an American app with a European guideline or vice versa.

Following the Cicchetti guidelines for interpretation of ICC interrater agreement measures, we identified an excellent level of IRR on all MARS domains (21). However, since all calculated limits of the 95% confidence intervals reach below 0.75, the ICC should not be regarded as truly excellent. Based on the ICC results for information, subjective app quality and likelihood of behavioural impact, we can conclude the IRR to be good to excellent. This is because the true ICC value supposes to land on any point within the ranges identified by the 95% CI. For

the engagement and aesthetics domain we conclude the IRR to be fair to excellent. For the functionality domain and the total MARS quality score, we conclude the IRR to be appropriate (14).

There are several limitation of the current study. First, despite thorough search of earlier specified digital distribution platforms, we cannot be certain that all currently available mobile applications with a parental decision support system handling fever in children were identified and assessed within this study. Second, only one out of the 3 applications (the FeverFriend app) identified 3 levels of risk as shown in table 2 and 3. The Kinsa app identified 5 levels of risk and the FeverApp app generally acknowledged only 2 levels of risk ('do not call a doctor' or 'call a doctor'), with exception of few alarming symptoms ('call a doctor now'). In the process of implementation only the advices with clearly urgent implication, for example 'call a doctor now', were triaged red. This process of stratification might have played a role in the over- and under- triaging tendency identified within the Kinsa and FeverApp app respectively. Third, we did not measure the user's intention to follow the advice given by the app. Therefore, no insight in the efficiency of gatekeeping tools and the effect it has on healthcare seeking behaviour in real life was obtained.

Future app design in the field of medical decision making should ensure that established, evidence-based guidelines are incorporated upfront, that reliable and transparent algorithm design is used (e.g. providing the decision tree that is used as metadata), ensure regular updates and reviews in case guidelines change, while focusing on quality assurance and user friendly design in the interface of the app.

Conclusion

E-health is expected to get a more prominent place within healthcare. Given the low operational cost, self-triage- and management mobile applications could lower the pressure on the healthcare system by empowering parents to self-manage in a safe and cost- effective manner (8). However, there are some potential negative aspects such as changing the waiting room prevalence and pretest probability due to self-triage, data privacy concerns, inequity in access to these apps as well as legal and ethical concerns.

Moreover the limited availability of evidence based parental decision support applications for fever in young children remains a weakness. In this study we identified the Kinsa app as the most evidence based mobile application at present.

The authors have no conflicts of interest to declare with regard to the topic discussed in this manuscript.

References

1. Nelson Textbook of Pediatrics [Internet]. [cited 2024 Sep 8]. Available from: https://elsevier-elibRARY.com/contents/fullcontent/15188720/epubcontent_v2/OEBPS/B978143770755700169X.htm
2. Villarejo-Rodríguez MG, Rodríguez-Martín B. Parents' and primary caregivers' conceptualizations of fever in children: A systematic review of qualitative studies. *Nurs Health Sci.* 2020 Jun;22(2):162–70.
3. Thompson AP, Nesari M, Hartling L, Scott SD. Parents' experiences and information needs related to childhood fever: A systematic review. *Patient Educ Couns.* 2020 Apr;103(4):750–63.
4. Walsh A, Edwards H. Management of childhood fever by parents: literature review. *J Adv Nurs.* 2006 Apr;54(2):217–27.
5. Chefdeville E, Pages AS. Parental management of children's fever: Assessment of knowledge and use of health record information. *Arch Pediatr.* 2019 Jul;26(5):275–81.
6. Green R, Jeena P, Kotze S, Lewis H, Webb D, Wells M. Management of acute fever in children: guideline for community healthcare providers and pharmacists. *S Afr Med J.* 2013 Sep;103(12):948–54.
7. Neill S, Roland D, Jones CHD, Thompson M, Lakhanpaul M. Information resources to aid parental decision-making on when to seek medical care for their acutely sick child: a narrative systematic review. *BMJ Open.* 2015 Dec;5(12):e008280.
8. Verzantvoort NCM, Teunis T, Verheij TJM, van der Velden AW. Self-triage for acute primary care via a smartphone application: Practical, safe and efficient? *PLoS One.* 2018;13(6):e0199284.

9. Buechi R, Faes L, Bachmann LM, Thiel MA, Bodmer NS, Schmid MK, et al. Evidence assessing the diagnostic performance of medical smartphone apps: a systematic review and exploratory meta-analysis. *BMJ Open*. 2017 Dec;7(12):e018280.
10. Jazayeri SMHM, Jamshidnezhad A. Top Mobile Applications in Pediatrics and Children's Health: Assessment and Intelligent Analysis Tools for a Systematic Investigation. *Malays J Med Sci*. 2019 Jan;26(1):5–14.
11. Stoyanov SR, Hides L, Kavanagh DJ, Zelenko O, Tjondronegoro D, Mani M. Mobile app rating scale: a new tool for assessing the quality of health mobile apps. *JMIR mHealth uHealth*. 2015 Mar;3(1):e27.
12. Schmeelk S, Davis A, Li Q, Shippey C, Utah M, Myers A, et al. Monitoring Symptoms of COVID-19: Review of Mobile Apps. *JMIR mHealth uHealth*. 2022 Jun;10(6):e36065.
13. Davalbhakta S, Advani S, Kumar S, Agarwal V, Bhoyar S, Fedirko E, et al. A Systematic Review of Smartphone Applications Available for Corona Virus Disease 2019 (COVID19) and the Assessment of their Quality Using the Mobile Application Rating Scale (MARS). *J Med Syst*. 2020 Aug;44(9):164.
14. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. *J Chiropr Med*. 2016 Jun;15(2):155–63.
15. Overview | Fever in under 5s: assessment and initial management | Guidance | NICE [Internet]. [cited 2024 Sep 8]. Available from: <https://www.nice.org.uk/guidance/NG143>
16. Office-Hours Telehealth Triage Protocols User's Guide Office-Hours Telephone Triage Protocols User's Guide 2023 Office-Hours Telehealth Triage Protocols User's Guide. 2009 [cited 2024 Sep 8]; Available from: www.cleartriage.com.
17. Feel Better Faster with the Kinsa App | Kinsa Health [Internet]. [cited 2024 Sep 8]. Available from: <https://home.kinsahealth.com/kinsa-app>
18. FeverFriendTM | Welcome [Internet]. [cited 2024 Sep 8]. Available from: <https://feverfriend.eu/>
19. Fever App [Internet]. [cited 2024 Sep 8]. Available from: <https://www.feverapp.de/en/>
20. Semigran HL, Linder JA, Gidengil C, Mehrotra A. Evaluation of symptom checkers for self diagnosis and triage: audit study. *BMJ*. 2015 Jul;351:h3480.
21. Cicchetti D V. Guidelines, Criteria, and Rules of Thumb for Evaluating Normed and Standardized Assessment Instruments in Psychology. *Psychol Assess*. 1994;6(4):284–90.